[{"id":"56b89687-7a36-4160-8a78-12dda1521d31","acronym":"","url":"https://clinicaltrials.gov/study/NCT04189614","created_at":"2023-04-19T23:05:06.642Z","updated_at":"2024-07-02T16:35:44.619Z","phase":"Phase 1b","brief_title":"An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04189614","lead_sponsor":"AbbVie","biomarkers":" PTK7","pipe":" | ","alterations":" PTK7 expression","tags":["PTK7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTK7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cofetuzumab pelidotin (ABBV-647)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/13/2020","start_date":" 02/13/2020","primary_txt":" Primary completion: 02/13/2024","primary_completion_date":" 02/13/2024","study_txt":" Completion: 02/13/2024","study_completion_date":" 02/13/2024","last_update_posted":"2023-06-27"}]